Ivania Rizo, M.D., DABOM, spokesperson for The Obesity Society and director of obesity medicine at Boston Medical Center
Key Safety Findings: 12.3% placebo-adjusted weight loss at 28 weeks Discontinuation rate: ~10% (predominantly GI-related) Adverse events: Mild-moderate nausea and diarrhea (consistent with GLP-1 class) Zero severe diarrhea cases reported No new safety signals vs
Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, et al
[5] [6] The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) have reviewed extensive safety data on semaglutide
Whilst berberine is generally considered safe when used appropriately, it is not without potential adverse effects and important safety considerations